Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
Willemoe GL, Hertel PB, Bartels A, Jensen MB, Balslev E, Rasmussen BB, Mouridsen H, Ejlertsen B, Brünner N. Willemoe GL, et al. Among authors: brunner n. Eur J Cancer. 2009 Sep;45(14):2528-36. doi: 10.1016/j.ejca.2009.05.029. Epub 2009 Jun 15. Eur J Cancer. 2009. PMID: 19535243 Clinical Trial.
TIMP-1 as a tumor marker in breast cancer--an update.
Würtz SO, Schrohl AS, Mouridsen H, Brünner N. Würtz SO, et al. Among authors: brunner n. Acta Oncol. 2008;47(4):580-90. doi: 10.1080/02841860802022976. Acta Oncol. 2008. PMID: 18465326 Review.
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
Hertel PB, Tu D, Ejlertsen B, Jensen MB, Balslev E, Jiang S, O'Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO. Hertel PB, et al. Among authors: brunner n. Breast Cancer Res Treat. 2012 Feb;132(1):225-34. doi: 10.1007/s10549-011-1896-1. Epub 2011 Dec 9. Breast Cancer Res Treat. 2012. PMID: 22160637 Clinical Trial.
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.
Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, Foekens JA, Brunner N, Holten-Andersen MN. Schrohl AS, et al. Among authors: brunner n. Mol Cell Proteomics. 2003 Mar;2(3):164-72. doi: 10.1074/mcp.M300019-MCP200. Epub 2003 Apr 2. Mol Cell Proteomics. 2003. PMID: 12672830 Free article.
595 results